REASON: A Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV. 31. Mai 2011 Dietel, M., Schütte, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Schirmacher, P., 2011. First line therapy with Bendamustine in advanced indolent Non-Hodgkin Lymphoma in treatment routine – interim analysis of the non-interventional study Be-1st. Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Grass, J., Straßl, L., 2011. Onkologie 34 (suppl.6)(P891), 268. doi:10.1159/000333305 Abstract… Weiterlesen EGFR mutation testing and first line treatment of patients with advanced NSCLC and positive EGFR mutation status: results from a German registry. Eberhardt, W., Thomas, M., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Gutendorf, P., Zirrgiebel, U., Schütte, W., 2011. EMCC / ESMO, European Multidisciplinary… Weiterlesen